

## Leadership Transition

### Leadership changes for planned U.S. Market Launch

**PERTH, Australia, 1 July 2025:** Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix® AI-powered cloud platform, for the real time, point of care assessment and management of coronary artery disease globally, announces that as part of the Company's evolution and preparation for U.S. commercialisation, key leadership positions will take effect on 1 July 2025. Mr John Konstantopoulos (Artrya's Co-Founder and currently Executive: Commercial & Strategy), will be appointed Chief Executive Officer. Mr Harvey Farrington (currently Artrya's Global Commercial Manager) will be appointed Acting Chief Financial Officer and Mr Bernie Ridgeway (currently Non-Executive Chair) will become Executive Chair.

#### Key Points

- **Evolution of leadership structure in preparation for U.S. commercial launch - Appointments effective from 1 July 2025**
- **Co-Founder John Konstantopoulos will be appointed Chief Executive Officer**
- **Mr Harvey Farrington, Global Commercial Manager, appointed as Acting Chief Financial Officer**
- **Mr Bernie Ridgeway, will become Executive Chair, supporting this next phase of the Company**

The leadership transition marks an exciting new chapter for Artrya as the Company shifts focus towards commercial growth and execution, and deeper engagement with clinical and commercial partners. Mr Konstantopoulos will lead this next phase supported by Harvey Farrington as Acting Chief Financial Officer, who brings strong financial and accounting expertise as well as experience working with Artrya's commercial partners.

Bernie Ridgeway will step into the role of Executive Chair, with his extensive listed company corporate and commercial experience, supporting this next phase of the Company's evolution.

Mr Konstantopoulos has been instrumental in architecting Artrya's near real-time, point-of-care technology to transform coronary artery disease diagnosis. He has also led the clinical and commercial growth of the Salix® technology platform, where he continues to play a pivotal role in driving U.S. partnerships, strategy, and engaging with the capital markets.

Bernie Ridgeway commented on the management changes:

*"John, as the next Chief Executive Officer, brings a strong clinical and commercial skillset to the role, as well as a deep knowledge of Artrya's technology, strategy, customers and investor stakeholders. John has been integral to building our network of clinical and commercial partners in both the U.S. and Australia, making him the perfect person to lead Artrya through the next phase of growth commercially."*

*"Harvey is a Chartered Accountant with extensive experience as a Commercial Manager across multiple organisations. He brings a strong background in strategic commercial and financial roles that have supported business growth and execution."*

*"I would also like to sincerely thank Mat Regan for his significant contributions over the past two years as CEO. Mat has reshaped our technology, ensuring we now have a robust clinical platform that supports hospitals and clinicians globally. Mat has overseen our FDA clearance for the Salix® Coronary Anatomy platform and our recent FDA submission for the Salix® Coronary Plaque module, leaving us well-positioned to execute on our planned commercial objectives."*

Commenting on his appointment, John Konstantopoulos said "I am very excited to lead Artrya as we rapidly transition into a highly focused, commercial enterprise. I believe there are tremendous opportunities for our business, leveraging the strong foundations of our world leading Salix® platform, our current partner network and our dedicated team. There is a global need for real time, point of care diagnostic solutions for coronary artery disease, and we will remain laser focused to commercially address these challenges and deliver results for our shareholders."

#### Additional details

The Employment Agreements for John Konstantopoulos and Bernie Ridgeway are summarised in **Annexure A** to this ASX Announcement, in accordance with ASX Listing Rule 3.16.4.

- Ends -

This ASX Announcement is authorised for release by the Board of Artrya Limited.

#### About Artrya

Artrya Limited (ASX: AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit [www.artrya.com](http://www.artrya.com) or follow us on LinkedIn at [www.linkedin.com/company/artrya](https://www.linkedin.com/company/artrya)

For more information:

#### Corporate Enquiries

##### John Konstantopoulos

Co-Founder and Chief Executive Officer

Tel: +61 8 6478 7816

Email: [contact@artrya.com](mailto:contact@artrya.com)

#### Investor & Media Enquiries

##### David Allen or John Granger

Hawkesbury Partners

Tel: +61 499 100 038 or +61 410 577 155

Email: [investors@artrya.com](mailto:investors@artrya.com)

## Annexure A

### Summary of Material Terms of Mr. Konstantopoulos' Employment

<b>Commencement date</b>	1 July 2025 *
<b>Position</b>	Chief Executive Officer or CEO
<b>Term</b>	Ongoing until terminated by either party
<b>Fixed Annual Remuneration</b>	\$350,000 per annum (plus statutory superannuation) subject to annual review
<b>Short Term &amp; Long Term incentives</b>	As CEO, Mr Konstantopoulos will be eligible to participate in both the STI and LTI programmes for an amount equal to a proportion of his annual remuneration, on terms which are to be agreed and approved by the Board.
<b>Notice Period</b>	6 months' notice by either party
<b>Post employment restraint</b>	Mr Konstantopoulos is subject to post employment non-solicit and non- compete undertakings for 12 months from the end of his active employment.
<b>Other *</b>	Mr Konstantopoulos Employment Agreement dated 1 April 2019 will be rescinded from 1 July 2025. This shall not constitute a vesting or bad leaver event and Mr Konstantopoulos shall have continuity of his employment with the Company.

## Summary of Material Terms of Mr. Ridgeway's Employment

<b>Commencement date</b>	1 July 2025 *
<b>Position</b>	Executive Chair of the Board
<b>Term</b>	Ongoing until terminated by either party
<b>Fixed Annual Remuneration</b>	\$150,000 per annum (0.4 FTE) (including statutory superannuation) subject to annual review
<b>Long Term incentive</b>	Mr Ridgeway is eligible to participate in the Company's LTI program. The issue of any equity securities will be subject to shareholder approval.
<b>Notice Period</b>	3 months' notice by either party
<b>Post employment restraint</b>	Mr Ridgeway is subject to post employment non-solicit and non-compete undertakings for 12 months from the end of his active executive employment.
<b>Other *</b>	Mr Ridgeway's current Non-Executive Director Agreement dated 8 February 2021 will be rescinded from 1 July 2025.